Kenya National Cancer Control Programme (NCCP) FHIR Implementation Guide
0.1.0 - ci-build
Kenya National Cancer Control Programme (NCCP) FHIR Implementation Guide
0.1.0 - ci-build
Kenya National Cancer Control Programme (NCCP) FHIR Implementation Guide, published by Digital Health Agency (DHA), Kenya. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/IntelliSOFT-Consulting/nccpFHIRIG/ and changes regularly. See the Directory of published versions
| Active as of 2026-06-04 |
{
"resourceType" : "CodeSystem",
"id" : "ocm-protocol-markers-cs",
"language" : "en",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: CodeSystem ocm-protocol-markers-cs</b></p><a name=\"ocm-protocol-markers-cs\"> </a><a name=\"hcocm-protocol-markers-cs\"> </a><p>This case-sensitive code system <code>https://nshr-uat.sha.go.ke/fhir/CodeSystem/ocm-protocol-markers-cs</code> defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td style=\"white-space:nowrap\">HER2-POSITIVE<a name=\"ocm-protocol-markers-cs-HER2-POSITIVE\"> </a></td><td>HER2 Positive</td><td>HER2/neu overexpression or amplification detected.</td></tr><tr><td style=\"white-space:nowrap\">HER2-NEGATIVE<a name=\"ocm-protocol-markers-cs-HER2-NEGATIVE\"> </a></td><td>HER2 Negative</td><td>No HER2/neu overexpression or amplification.</td></tr><tr><td style=\"white-space:nowrap\">ER-POSITIVE<a name=\"ocm-protocol-markers-cs-ER-POSITIVE\"> </a></td><td>ER Positive</td><td>Oestrogen receptor positive.</td></tr><tr><td style=\"white-space:nowrap\">ER-NEGATIVE<a name=\"ocm-protocol-markers-cs-ER-NEGATIVE\"> </a></td><td>ER Negative</td><td>Oestrogen receptor negative.</td></tr><tr><td style=\"white-space:nowrap\">PR-POSITIVE<a name=\"ocm-protocol-markers-cs-PR-POSITIVE\"> </a></td><td>PR Positive</td><td>Progesterone receptor positive.</td></tr><tr><td style=\"white-space:nowrap\">PR-NEGATIVE<a name=\"ocm-protocol-markers-cs-PR-NEGATIVE\"> </a></td><td>PR Negative</td><td>Progesterone receptor negative.</td></tr><tr><td style=\"white-space:nowrap\">TRIPLE-NEGATIVE<a name=\"ocm-protocol-markers-cs-TRIPLE-NEGATIVE\"> </a></td><td>Triple Negative</td><td>ER-, PR-, HER2- breast cancer.</td></tr><tr><td style=\"white-space:nowrap\">KRAS-MUTANT<a name=\"ocm-protocol-markers-cs-KRAS-MUTANT\"> </a></td><td>KRAS Mutant</td><td>KRAS mutation detected.</td></tr><tr><td style=\"white-space:nowrap\">KRAS-WILD-TYPE<a name=\"ocm-protocol-markers-cs-KRAS-WILD-TYPE\"> </a></td><td>KRAS Wild-type</td><td>No KRAS mutation.</td></tr><tr><td style=\"white-space:nowrap\">BRAF-V600E<a name=\"ocm-protocol-markers-cs-BRAF-V600E\"> </a></td><td>BRAF V600E Mutant</td><td>BRAF V600E mutation detected.</td></tr><tr><td style=\"white-space:nowrap\">PD-L1-POSITIVE<a name=\"ocm-protocol-markers-cs-PD-L1-POSITIVE\"> </a></td><td>PD-L1 Positive</td><td>PD-L1 expression ≥1%.</td></tr><tr><td style=\"white-space:nowrap\">PD-L1-NEGATIVE<a name=\"ocm-protocol-markers-cs-PD-L1-NEGATIVE\"> </a></td><td>PD-L1 Negative</td><td>PD-L1 expression <1%.</td></tr><tr><td style=\"white-space:nowrap\">MSI-HIGH<a name=\"ocm-protocol-markers-cs-MSI-HIGH\"> </a></td><td>MSI-High</td><td>Microsatellite instability high.</td></tr><tr><td style=\"white-space:nowrap\">MSI-LOW<a name=\"ocm-protocol-markers-cs-MSI-LOW\"> </a></td><td>MSI-Low / MSS</td><td>Microsatellite instability low or stable.</td></tr><tr><td style=\"white-space:nowrap\">EGFR-MUTANT<a name=\"ocm-protocol-markers-cs-EGFR-MUTANT\"> </a></td><td>EGFR Mutant</td><td>EGFR mutation detected.</td></tr><tr><td style=\"white-space:nowrap\">ALK-POSITIVE<a name=\"ocm-protocol-markers-cs-ALK-POSITIVE\"> </a></td><td>ALK Positive</td><td>ALK rearrangement detected.</td></tr><tr><td style=\"white-space:nowrap\">NOT-TESTED<a name=\"ocm-protocol-markers-cs-NOT-TESTED\"> </a></td><td>Not Tested</td><td>Biomarker testing not performed.</td></tr></table></div>"
},
"url" : "https://nshr-uat.sha.go.ke/fhir/CodeSystem/ocm-protocol-markers-cs",
"version" : "0.1.0",
"name" : "OCMProtocolMarkersCS",
"title" : "Kenya OCM Protocol Markers Code System",
"status" : "active",
"experimental" : false,
"date" : "2026-06-04T14:49:30+00:00",
"publisher" : "Digital Health Agency (DHA), Kenya",
"contact" : [
{
"name" : "Digital Health Agency (DHA), Kenya",
"telecom" : [
{
"system" : "url",
"value" : "https://dha.go.ke"
},
{
"system" : "email",
"value" : "info@dha.go.ke"
}
]
},
{
"name" : "Digital Health Agency Kenya – FHIR Team",
"telecom" : [
{
"system" : "email",
"value" : "info@dha.go.ke",
"use" : "work"
},
{
"system" : "url",
"value" : "https://dha.go.ke",
"use" : "work"
}
]
}
],
"description" : "Biomarker and molecular marker codes used for treatment protocol selection.",
"jurisdiction" : [
{
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "KE",
"display" : "Kenya"
}
]
}
],
"caseSensitive" : true,
"content" : "complete",
"count" : 17,
"concept" : [
{
"code" : "HER2-POSITIVE",
"display" : "HER2 Positive",
"definition" : "HER2/neu overexpression or amplification detected."
},
{
"code" : "HER2-NEGATIVE",
"display" : "HER2 Negative",
"definition" : "No HER2/neu overexpression or amplification."
},
{
"code" : "ER-POSITIVE",
"display" : "ER Positive",
"definition" : "Oestrogen receptor positive."
},
{
"code" : "ER-NEGATIVE",
"display" : "ER Negative",
"definition" : "Oestrogen receptor negative."
},
{
"code" : "PR-POSITIVE",
"display" : "PR Positive",
"definition" : "Progesterone receptor positive."
},
{
"code" : "PR-NEGATIVE",
"display" : "PR Negative",
"definition" : "Progesterone receptor negative."
},
{
"code" : "TRIPLE-NEGATIVE",
"display" : "Triple Negative",
"definition" : "ER-, PR-, HER2- breast cancer."
},
{
"code" : "KRAS-MUTANT",
"display" : "KRAS Mutant",
"definition" : "KRAS mutation detected."
},
{
"code" : "KRAS-WILD-TYPE",
"display" : "KRAS Wild-type",
"definition" : "No KRAS mutation."
},
{
"code" : "BRAF-V600E",
"display" : "BRAF V600E Mutant",
"definition" : "BRAF V600E mutation detected."
},
{
"code" : "PD-L1-POSITIVE",
"display" : "PD-L1 Positive",
"definition" : "PD-L1 expression ≥1%."
},
{
"code" : "PD-L1-NEGATIVE",
"display" : "PD-L1 Negative",
"definition" : "PD-L1 expression <1%."
},
{
"code" : "MSI-HIGH",
"display" : "MSI-High",
"definition" : "Microsatellite instability high."
},
{
"code" : "MSI-LOW",
"display" : "MSI-Low / MSS",
"definition" : "Microsatellite instability low or stable."
},
{
"code" : "EGFR-MUTANT",
"display" : "EGFR Mutant",
"definition" : "EGFR mutation detected."
},
{
"code" : "ALK-POSITIVE",
"display" : "ALK Positive",
"definition" : "ALK rearrangement detected."
},
{
"code" : "NOT-TESTED",
"display" : "Not Tested",
"definition" : "Biomarker testing not performed."
}
]
}